Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending multiple-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo. Subjects will be dosed daily for 14 days.

Timeline

Start

2012-01

Primary completion

2012-11

Completion

2012-11

Drugs

Indications

No indication recorded.